Forward Price-to-Revenue Multiple: CureVac Corp (CVAC)

CureVac Pharma (CVAC) - corporate logo

CureVac N.V. (CVAC) price action is tied to the outcomes of oncology and influenza trials, with the 12.80 metric serving as the target level. The forward P/S ratio reflects the current balance of demand, helping to assess the market discount. The German mRNA pioneer is valued for its scientific authority, while strategic alliances with pharmaceutical behemoths accelerate the market launch of new drugs.

CVAC curevac.com: Forward Price to Sales in the range 07/04/2022 - 01/17/2026

CureVac Pharma (CVAC) - metric breakdowns and financial figures

- current price and projected stock value:
Stock Price CureVac|CVAC - Consensus Target
- company stock exchange capitalization indicators:
Market Valuation CureVac Pharma|CVAC - Enterprise Value
- business book valuation details:
Net Assets per Single Share CureVac|CVAC - Accounting Value of Company|Market Capitalization to Book Value Ratio curevac.com|CVAC - Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio CureVac N.V.|CVAC - Long-Term Debt to Equity|Short-Term Debt to Capital CureVac N.V.|CVAC - Company Aggregate Debts|Debts to Book Capitalization CureVac Pharma|CVAC - Company Long-Term Liabilities|Company Current Liabilities CureVac|Quick Liquidity curevac.com
- business earnings and investment ratios data:
CVAC - Company Profit|Future Profit CureVac N.V.|CVAC - Business Payback Period|Projected Price to Earnings CureVac Corp|CVAC - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio CureVac Pharma|CVAC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) CureVac|CVAC - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months curevac.com|CVAC - Earnings per share growth in current year|Earnings growth forecast for next year CureVac N.V.
- company sales and revenue statistics:
CVAC - Revenue and Sales Volume|Projected Sales Volume CureVac|CVAC - Market Cap to Revenue|Price-to-Projected Revenue Ratio CureVac Pharma
Fundamental company analysis:CureVac CVAC
Manufactured products of CureVac Pharma

Investors utilize forward multiples to verify an asset's fair value through expected cash flows. The projected price-to-sales ratio measures the company's market value relative to its forecasted sales, reflecting the valuation's sensitivity to the cost of capital. This chart's price action allows for an assessment of market optimism regarding the commercialization of vaccines with GSK and oncology therapies. The compression of this metric confirms the fundamental strengthening of CureVac N.V. (CVAC) in the eyes of the market.

Competitors of CureVac N.V. (CVAC)

Forward P/S Multiple GILD (Gilead Sciences)|CDTX - Forward Price-to-Revenue Multiple|NVAX: Forward Price-to-Revenue Multiple|VALN - Forward P/S Multiple|Vir Biotechnology, Inc. (VIR) - Price-to-Projected Revenue Ratio|siga.com - Forward Price to Sales|EBS (Emergent BioSolutions Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Atea Pharma AVIR|Forward Price-to-Revenue Multiple IVVD (Invivyd, Inc.)|Price-to-Projected Revenue Ratio ENTA (Enanta Pharmaceuticals, Inc)|Forward P/S Multiple INO (Inovio Pharmaceuticals)|Forward P/S Multiple hillevax.com HLVX|Kalaris Therapeutics - Forward P/S Multiple|Dyadic International (DYAI) - Forward Price-to-Revenue Multiple|NNVC (nanoviricides.com) - Forward Price-to-Revenue Multiple|Talphera Corporation - Forward Price to Sales|Price-to-Projected Revenue Ratio Cocrystal Pharma, Inc.|Market Cap to Projected Revenue TRAW (Traws Therapeutics)|Forward Price-to-Revenue Multiple DWTX (Dogwood Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Qualigen Therapeutics Inc|AlloVir - Forward Price-to-Revenue Multiple|VBI Vaccines, Inc. - Price-to-Projected Revenue Ratio|VIRI: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Vaxart, Inc. VXRT